Blood Products
Blood products within the responsibility of the Paul-Ehrlich-Institut (PEI) comprise human blood components for transfusion and proteins either derived from human plasma or biotechnologically engineered.
Updated: 21.11.2019
Paul-Ehrlich-Institut
You are here:
- Medicinal Products
- Blood Products
Subnavigation of all website sections
Medicinal Products
Regulation
- Advice
- Clinical Trials
- Marketing Authorisation (Human)
- Marketing Authorisation (Veterinary)
- Approvals
- Batch Testing (Human)
- Batch Testing (Veterinary)
- Inspections
- Reference Material
- Electronic Submission
- Fees
- Testing Laboratory IVD
- Reporting Obligations
- Quality Management
Newsroom
- News
- Press Releases
- Positions
- PEI Biennial Reports
- Mandatory Reports
- Social Media
- Events
- Publications on Medicines
- Videos, Audios and Infographics
- WHO CC Annual Reports
- Centralised Authorisations
- Coronavirus and COVID-19
- Brexit
- HIV Self-tests
- Notifications for Medical and Pharmaceutical Professionals
The Paul-Ehrlich-Institut is an Agency of the German Federal Ministry of Health.
Its research and control activities promote the quality, efficacy and safety of biological medicinal products.
© Paul-Ehrlich-Institut 2022 ImprintPrivacy Policy